Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Insulin sensitisation in post-menarcheal girls with a history of low birthweight and precocious pubarche: effects of the addition of antiandrogen treatment and of the androgen receptor length on body composition and endocrine-metabolic parameters
ISRCTN ISRCTN08608368
ClinicalTrials.gov identifier
Public title Insulin sensitisation in post-menarcheal girls with a history of low birthweight and precocious pubarche: effects of the addition of antiandrogen treatment and of the androgen receptor length on body composition and endocrine-metabolic parameters
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis The endocrine-metabolic effects of insulin sensitisation +/- antiandrogen therapy will be directly related to the length of CAG repeats of the androgen receptor gene.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Spain
Disease/condition/study domain Ovarian hyperandrogenism
Participants - inclusion criteria 1. Post-menarcheal state
2. A history of low birthweight and precocious pubarche
3. Subclinical ovarian hyperandrogenism
4. Hyperinsulinemia
Participants - exclusion criteria 1. Clinical signs of androgen excess
2. Family or personal history of diabetes mellitus
3. Late-onset congenital adrenal hyperplasia
Anticipated start date 20/10/2003
Anticipated end date 20/10/2006
Status of trial Completed
Patient information material
Target number of participants 20
Interventions Insulin sensitisation +/- antiandrogen treatment
Primary outcome measure(s) 1. Development of clinical hyperandrogenism
2. Body composition
Secondary outcome measure(s) 1. Decrease of androgens
2. Improvement of insulin sensitivity
Sources of funding Hospital Sant Joan de Deu (Spain)
Trial website
Publications 2007 results in http://www.ncbi.nlm.nih.gov/pubmed/17984247
Contact name Prof  Lourdes  Ibañez
  Address Hospital Sant Joan de Deu
Passeig de Sant Joan de Deu 2
  City/town Esplugues, Barcelona
  Zip/Postcode 08950
  Country Spain
Sponsor Hospital Sant Joan de Deu (Spain)
  Address Passeig de Sant Joan de Deu, 2
  City/town Esplugues, Barcelona
  Zip/Postcode 08950
  Country Spain
Date applied 07/09/2005
Last edited 11/09/2009
Date ISRCTN assigned 05/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central